agents	treat	leishmaniasis
agents	treat	trypanosomiasis
agents	are	antiparasitic
agents	include	pentamidine
agents	include	miltefosine
agents	include	amphotericin B
agents	include	nifurtimox
agents	include	benznidazole
pentamidine	used for	visceral leishmaniasis
pentamidine	used for	cutaneous leishmaniasis
pentamidine	used for	mucocutaneous leishmaniasis
pentamidine	used for	Chagas disease
pentamidine	contraindicated in	pregnancy
pentamidine	causes	nephrotoxicity
pentamidine	causes	hypoglycemia
pentamidine	causes	hypotension
pentamidine	dosage	5 mg/kg
pentamidine	route	intravenous
pentamidine	route	intramuscular
pentamidine	efficacy	80%
miltefosine	first line for	cutaneous leishmaniasis
miltefosine	first line for	mucocutaneous leishmaniasis
miltefosine	first line for	visceral leishmaniasis
miltefosine	contraindicated in	pregnancy
miltefosine	causes	gastrointestinal upset
miltefosine	causes	teratogenicity
miltefosine	causes	hepatotoxicity
miltefosine	dosage	2.5 mg/kg/day
miltefosine	route	oral
miltefosine	efficacy	70%
amphotericin B	used for	severe visceral leishmaniasis
amphotericin B	used for	refractory cutaneous leishmaniasis
amphotericin B	used for	mucocutaneous leishmaniasis
amphotericin B	used for	Chagas disease
amphotericin B	causes	nephrotoxicity
amphotericin B	causes	infusion reactions
amphotericin B	causes	hypokalemia
amphotericin B	dosage	0.3–0.5 mg/kg/day
amphotericin B	route	intravenous
amphotericin B	efficacy	90%
nifurtimox	used for	Chagas disease
nifurtimox	used for	early-stage trypanosomiasis
nifurtimox	causes	gastrointestinal upset
nifurtimox	causes	neuropathy
nifurtimox	causes	hepatotoxicity
nifurtimox	dosage	10–20 mg/kg/day
nifurtimox	route	oral
nifurtimox	efficacy	60%
benznidazole	used for	Chagas disease
benznidazole	used for	early-stage trypanosomiasis
benznidazole	causes	dermatitis
benznidazole	causes	neuropathy
benznidazole	causes	hepatotoxicity
benznidazole	dosage	5–10 mg/kg/day
benznidazole	route	oral
benznidazole	efficacy	70%
agents	have	side effects
agents	have	drug interactions
agents	require	monitoring
agents	require	liver function tests
agents	require	renal function tests
agents	require	blood glucose monitoring
agents	require	pregnancy screening
agents	can cause	anemia
agents	can cause	thrombocytopenia
agents	can cause	leukopenia
agents	can cause	cardiotoxicity
agents	can cause	arrhythmias
agents	can cause	QT prolongation
agents	can cause	ocular toxicity
agents	can cause	hearing loss
agents	can cause	visual disturbances
agents	can cause	rash
agents	can cause	fever
agents	can cause	chills
agents	can cause	headache
agents	can cause	dizziness
agents	can cause	fatigue
agents	can cause	insomnia
agents	can cause	depression
agents	can cause	anxiety
agents	can cause	suicidal ideation
agents	can cause	seizures
agents	can cause	liver failure
agents	can cause	kidney failure
agents	can cause	bone marrow suppression
agents	can cause	hypersensitivity
agents	can cause	anaphylaxis
agents	can cause	Stevens-Johnson syndrome
agents	can cause	toxic epidermal necrolysis
agents	can cause	drug-induced lupus
agents	can cause	pulmonary toxicity
agents	can cause	interstitial lung disease
agents	can cause	pulmonary hypertension
agents	can cause	cardiac arrest
agents	can cause	death
agents	are	prescription drugs
agents	are	regulated by FDA
agents	are	regulated by EMA
agents	are	subject to pharmacovigilance
